摘要
目的评价阿卡波糖治疗2型糖尿病(T2DM)的经济学效益。方法收集T2DM 88例患者资料,将患者采用随机数字表法分为两组,各44例。A组患者应用阿卡波糖治疗,B组患者应用二甲双胍治疗,比较两组患者的成本(C)/疗效(E)比。结果两组患者治疗后FPG及2 h PG均较治疗前明显降低(P<0.05),两组患者治疗后FPG水平比较差异无统计学意义(P>0.05),但A组的2 h PG明显低于B组;以FPG为疗效指标,两组比较差异无统计学意义(P>0.05);以2 h PG为疗效标准,A组总有效率明显高于B组(P<0.05);A组FPG、2 h PG的C/E分别为6.42、5.82,明显高于B组的3.25、3.34(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿卡波糖控制FPG的疗效与二甲双胍相当,但控制2 h PG疗效优于二甲双胍,从疗效经济学角度分析,阿卡波糖低于二甲双胍,临床应根据患者的具体情况合理选择用药。
Objective To evaluate the effect of acarbose in treatment of type 2 diabetes mellitus（T2DM）economic benefit.Methods Collect the data of 88 cases of T2DM patients,the patients were randomly divided into two groups, 44 cases in each.A group of patients with acarbose in the treatment of patients in the B group,metformin treatment, compared two groups of patients with curative effect cost（C）/（E）ratio.Resu｜ts The two groups after the treatment of FPG and 2 hPG were significantly lower than those before treatment（P〈0.05）,the two groups had no statistically significant differences in FPG level after treatment（P~ 0.05）,but the 2 hPG A group was significantly lower than that in B group;FPG as indicators of efficacy, the difference between the two groups had no statistical signifi- cance（P〉O.05）; with 2 hPG as the standard of curative effect,the total effective rate of group A was significantly higher than that of B group（P〈0.05）;group A,2 FPG hPG C/E were 6.42,5.82,significantly higher than that of B group,3.25, 3.34（P〈0.05）; the adverse effects of the two groups compared, the difference was not statistically significance（P〉O.O5）.Conclusion the therapeutic effect of acarbose and metformin control FPG quite, but the control effect of 2 hPG is better than that from the perspective of economics analysis of curative effect of metformin, acarbose and metformin, below the clinical medication,should be a reasonable choice according to the specific condition of patients.
出处
《中国药物经济学》
2015年第6期27-29,共3页
China Journal of Pharmaceutical Economics
关键词
2型糖尿病
阿卡波糖
临床疗效
药物经济学
Type 2 diabetes mellitus
Acarbose
Clinical efficacy
Pharmacoeconomics
